CpG island methylator phenotype and childhood leukemia

Clinical Cancer Research

Volumn 12, Issue 16, 2006, Pages 4787-4789

  Lacayo, Norman J ^a   DiMartino, Jorge F ^b   Wei, Michael C ^a   Dahl, Gary V ^a  

^a STANFORD UNIVERSITY   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE; PROTEIN P16INK4A;

ACUTE GRANULOCYTIC LEUKEMIA; CHILDHOOD LEUKEMIA; CPG ISLAND; DNA METHYLATION; HUMAN; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NOTE; PHENOTYPE; PRENATAL PERIOD; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

CORE BINDING FACTOR ALPHA 2 SUBUNIT; CPG ISLANDS; DNA METHYLATION; DNA-BINDING PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MEMBRANE PROTEINS; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEINS;

EID: 33748345578     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0651     Document Type: Note

References (27)

1. Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. CpG island methylator phenotype redefines the prognostic impact of t(12;21) in childhood acute lymphoblastic leukemia. Clin Cancer Res 2006;12:4845-50.
2. Golub TR, Barker GF, Bohlander SK, et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 1995;92:4917-21.
3. Bernard OA, Romana SP, Poirel H, Berger R. Molecular cytogenetics of t(12;21, p13;q22). Leuk Lymphoma 1996;23:459-65.
4. Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995;9:1985-9.
5. Loh ML, Goldwasser MA, Silverman LB, et al. Prospective analysis of TEL/AML1 positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood 2006;107:4508-13.
6. Papadhimitriou SI, Polychronopoulou S, Tsakiridou AA, Androutsos G, Paterakis GS, Athanassiadou F. p16 inactivation associated with aggressive clinical course and fatal outcome in TEL/AML1-positive acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2005;27:675-7.
7. Ly-Sunnaram B, Henry C, Gandemer V, et al. Late ovarian relapse of TEL/AML1 positive ALL confirming that TEL deletion is a secondary event in leukemogenesis. Leuk Res 2005;29:1089-94.
8. McHale CM, Wiemels JL, Zhang L, et al. Prenatal origin of TEL-AML1-positive acute lymphoblastic leukemia in children born in California. Genes Chromosomes Cancer 2003;37:36-43.
9. Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 1999;354:1499-503.
10. Teuffel O, Betts DR, Dettling M, Schaub R, Schafer BW, Niggli FK. Prenatal origin of separate evolution of leukemia in identical twins. Leukemia 2004;18:1624-9.
11. Zuna J, Ford AM, Peham M, et al. TEL deletion analysis supports a novel view of relapse in childhood acute lymphoblastic leukemia. Clin Cancer Res 2004;10:5355-60.
12. Rothman R, Trakhtenbrot L, Bielorai B, et al. Co-existence of multiple subclones in TEL-AML1 at diagnosis of acute lymphoblastic leukaemia in association with submicroscopic deletion of AML1. Br J Haematol 2005;129:491-8.
13. Melnick AM, Adelson K, Licht JD. The theoretical basis of transcriptional therapy of cancer: can it be put into practice? J Clin Oncol 2005;23:3957-70.
14. Lin HY, Chen CS, Lin SP, Weng JR. Targeting histone deacetylase in cancer therapy. Med Res Rev 2006;26:397-413.
15. Toyota M, Ahuja N, Suzuki H, et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999;59:5438-42.
16. Melki JR, Warnecke P, Vincent PC, Clark SJ. Increased DNA methyltransferase expression in leukaemia. Leukemia 1998;12:311-6.
17. Asimakopoulos FA, Shteper PJ, Krichevsky S, et al. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood 1999;94:2452-60.
18. Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 1999;59:3730-40.
19. Esteller M. Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin Immunol 2003;109:80-8.
20. Sweetser DA, Chen CS, Blomberg AA, et al. Loss of heterozygosity in childhood de novo acute myelogenous leukemia. Blood 2001;98:1188-94.
21. Seedhouse CH, Das-Gupta EP, Russell NH. Methylation of the hMLH1 promoter and its association with microsatellite instability in acute myeloid leukemia. Leukemia 2003;17:83-8.
22. Ekmekci CG, Gutierrez MI, Siraj AK, Ozbek U, Bhatia K. Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. Am J Hematol 2004;77:233-40.
23. Lasa A, Carnicer MJ, Aventin A, et al. MEIS 1 expression is downregulated through promoter hypermethylation in AML1ETO acute myeloid leukemias. Leukemia 2004;18:1231-7.
24. Voso MT, Scardocci A, Guidi F, et al. Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood 2004;103:698-700.
25. Chim CS, Wong SY, Pang A, et al. Aberrant promoter methylation of the retinoic acid receptor α gene in acute promyelocytic leukemia. Leukemia 2005;19:2241-6.
26. Iwai M, Kiyoi H, Ozeki K, et al. Expression and methylation status of the FHIT gene in acute myeloid leukemia and myelodysplastic syndrome. Leukemia 2005;19:1367-75.
27. DiMartino JF, Lacayo NJ, Varadi M, et al. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia 2006;20:426-32.